Atypical Hemolytic Uremic Syndrome Caused by a Rare Complement Factor B Mutation.

Area of Science:

• Nephrology
• Hematology
• Immunology

Background:

• Thrombotic microangiopathy (TMA) is a rare condition characterized by thrombocytopenia, hemolytic anemia, and organ damage.
• Hemolytic uremic syndrome (HUS) is a common form of TMA, often caused by Shiga toxin-producing E. coli, but atypical HUS (aHUS) involves other mechanisms.
• Complement-mediated thrombotic microangiopathy (C-TMA) is a subset of aHUS, typically hereditary due to complement regulatory factor mutations.

Observation:

• A middle-aged Caucasian male presented with a complex clinical picture suggestive of TMA.
• Diagnostic workup revealed atypical HUS, which was challenging due to its rarity.
• Genetic analysis identified a novel mutation in complement factor B as the underlying cause.

Findings:

• The patient's aHUS was attributed to a specific mutation in complement factor B.
• This finding underscores the genetic heterogeneity of complement-mediated thrombotic microangiopathy.
• The case highlights the diagnostic difficulties associated with rare TMA presentations.

Implications:

• Accurate diagnosis of rare TMA etiologies, including complement factor mutations, is essential for guiding treatment.
• Timely and precise diagnosis can lead to more favorable prognoses for patients with atypical HUS.
• This case emphasizes the importance of considering genetic testing in unexplained TMA cases.